Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.


Journal Article

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

Full Text

Duke Authors

Cited Authors

  • Levin, MJ; Schmader, KE; Gnann, JW; McNeil, SA; Vesikari, T; Betts, RF; Keay, S; Stek, JE; Bundick, ND; Su, S-C; Zhao, Y; Li, X; Chan, ISF; Annunziato, PW; Parrino, J

Published Date

  • November 1, 2013

Published In

Volume / Issue

  • 208 / 9

Start / End Page

  • 1386 - 1390

PubMed ID

  • 23908486

Pubmed Central ID

  • 23908486

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jit342


  • eng

Conference Location

  • United States